AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15909264 — intervention group
Group type: COMPARATOR
Intervention: Per-test calculations with index cutoff value of 1.5
Number of subjects: 315
Study 15909264 — intervention group
Group type: COMPARATOR
Intervention: Per-test calculations with index cutoff value of 0.5
Number of subjects: 315
Study 12492201 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg b.i.d.
Number of subjects: 801
Study 12492201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 801
Study 9951478 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography
Number of subjects: 19
Study 7811172 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-storing foot (Proteor)
Number of subjects: 24
Study 7811172 — intervention group
Group type: COMPARATOR
Intervention: SACH foot
Number of subjects: 24
Study 2108645 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (Eminase)
Number of subjects: 0
Study 108715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg haloperidol intravenous (IV)
Number of subjects: 7
Study 108715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg haloperidol intravenous (IV)
Number of subjects: 7
Study 108715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg haloperidol intramuscular (IM)
Number of subjects: 7
Study 108715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg haloperidol intramuscular (IM)
Number of subjects: 7
Study 30745518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosravuconazole (100 mg orally once a day for 12 weeks)
Number of subjects: 0
Study 28599665 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs capsules (1.8g EPA and 1.2g DHA)
Number of subjects: 42
Study 28599665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 42
Study 25796419 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sucrose octasulfate nasal gel (Silsos gel®)
Number of subjects: 34
Study 25796419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carbopol and propylene glycol)
Number of subjects: 34
Study 25022114 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (acupuncture and auricle cutting)
Number of subjects: 56
Study 25022114 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricle cutting (sham-acupuncture and auricle cutting)
Number of subjects: 56
Study 25022114 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (acupuncture and sham auricle cutting)
Number of subjects: 56
Study 25022114 — intervention group
Group type: COMPARATOR
Intervention: Control (sham-acupuncture and sham auricle cutting)
Number of subjects: 56
Study 23288261 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 40
Study 23288261 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 40
Study 19957790 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 39
Study 19957790 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm (SR) group
Number of subjects: 39
Study 18322606 — intervention group
Group type: EXPERIMENTAL
Intervention: KGQG
Number of subjects: 57
Study 18322606 — intervention group
Group type: COMPARATOR
Intervention: Routine medications
Number of subjects: 57
Study 14699491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil/lamivudine
Number of subjects: 59
Study 14699491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil
Number of subjects: 59
Study 14699491 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 59
Study 14699491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil or adefovir dipivoxil/lamivudine
Number of subjects: 59
Study 12219889 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual discrimination task with retention intervals of 50 msec to 800 msec
Number of subjects: 0
Study 9822002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to generate an airway pressure of 20 cm water
Number of subjects: 150
Study 9822002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to ventilate manually
Number of subjects: 150
Study 9822002 — intervention group
Group type: EXPERIMENTAL
Intervention: Black line on the LMA in midline
Number of subjects: 150
Study 9822002 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior movement of the larynx
Number of subjects: 150
Study 9822002 — intervention group
Group type: EXPERIMENTAL
Intervention: Outward movement of the LMA on inflation of the cuff
Number of subjects: 150
Study 9822002 — intervention group
Group type: EXPERIMENTAL
Intervention: Movements of the reservoir bag with spontaneous breathing
Number of subjects: 150
Study 9822002 — intervention group
Group type: COMPARATOR
Intervention: Presence of resistance at the end of insertion
Number of subjects: 150
Study 9822002 — intervention group
Group type: COMPARATOR
Intervention: Inability to advance LMA after inflation of the cuff
Number of subjects: 150
Study 9822002 — intervention group
Group type: COMPARATOR
Intervention: Presence of a capnographic trace
Number of subjects: 150
Study 10580682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 74
Study 10580682 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate
Number of subjects: 74
Study 1669241 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 5000
Study 1669241 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 5000
Study 6839797 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sulindac twice daily
Number of subjects: 30
Study 6839797 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ibuprofen 3-times daily
Number of subjects: 30
Study 29253915 — intervention group
Group type: EXPERIMENTAL
Intervention: Health programme (Intervention Group)
Number of subjects: 552
Study 29253915 — intervention group
Group type: COMPARATOR
Intervention: Survey (Control Group)
Number of subjects: 552
Study 29937258 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills (CLAS)
Number of subjects: 199
Study 29937258 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused treatment (PFT)
Number of subjects: 199
Study 27180620 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + box lesion
Number of subjects: 176
Study 27180620 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + box lesion + LAA excision
Number of subjects: 176
Study 27180620 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 176
Study 22101443 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical care (CCU)
Number of subjects: 153
Study 22101443 — intervention group
Group type: COMPARATOR
Intervention: Surgical ward care
Number of subjects: 153
Study 22101443 — intervention group
Group type: COMPARATOR
Intervention: Ward care (for patients with anaerobic threshold >= 11 ml oxygen per kg per min)
Number of subjects: 153
Study 20696797 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Initiative in Rectal Cancer strategy
Number of subjects: 1015
Study 20696797 — intervention group
Group type: COMPARATOR
Intervention: Normal practice (control)
Number of subjects: 1015
Study 18269144 — intervention group
Group type: EXPERIMENTAL
Intervention: Moria M2 microkeratome
Number of subjects: 33
Study 18269144 — intervention group
Group type: EXPERIMENTAL
Intervention: SCHWIND Carriazo‐Pendular microkeratome
Number of subjects: 33
Study 18269144 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser
Number of subjects: 33
Study 16432641 — intervention group
Group type: EXPERIMENTAL
Intervention: Chipped ice in a plastic bag (cold group)
Number of subjects: 40
Study 16432641 — intervention group
Group type: COMPARATOR
Intervention: Room temperature water in a plastic bag (control group)
Number of subjects: 40
Study 14555886 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker bisoprolol (5 mg/day)
Number of subjects: 10
Study 14555886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10759937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 10
Study 10759937 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 9307933 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.8 g highly purified EPA
Number of subjects: 58
Study 9307933 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g DHA
Number of subjects: 58
Study 9307933 — intervention group
Group type: COMPARATOR
Intervention: corn oil
Number of subjects: 58
Study 8165609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay u3405 (thromboxane A2 receptor antagonist)
Number of subjects: 12
Study 8165609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8165609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay u3405
Number of subjects: 12
Study 3532011 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms twice daily via pear spacer (PS)
Number of subjects: 25
Study 3532011 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 200 micrograms twice daily directly from metered dose inhaler
Number of subjects: 25
Study 30920878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic radiotherapy (21 Gy in three fractions over three consecutive working days)
Number of subjects: 375
Study 30920878 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic radiotherapy
Number of subjects: 375
Study 30920878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic radiotherapy
Number of subjects: 375
Study 27632019 — intervention group
Group type: COMPARATOR
Intervention: Low-fat/high-sucrose (SUCR) meal
Number of subjects: 30
Study 27632019 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA meal
Number of subjects: 30
Study 27632019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 30
Study 27654255 — intervention group
Group type: EXPERIMENTAL
Intervention: Vintafolide (2.5 mg intravenously, 3 times per week, weeks 1 and 3, every 28 days) + Pegylated Liposomal Doxorubicin (50 mg/m intravenously, day 1, every 28 days)
Number of subjects: 94
Study 27654255 — intervention group
Group type: COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin alone (50 mg/m intravenously, day 1, every 28 days)
Number of subjects: 94
Study 27654255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Vintafolide + PLD)
Number of subjects: 94
Study 27654255 — intervention group
Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 94
Study 24001457 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait Positive Arousal
Number of subjects: 52
Study 24001457 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait Negative Arousal
Number of subjects: 52
Study 24001457 — intervention group
Group type: EXPERIMENTAL
Intervention: Left NAcc activity during anticipation of large gains (+$5.00)
Number of subjects: 52
Study 24001457 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anterior insula activity during anticipation of large losses (‐$5.00)
Number of subjects: 52
Study 22214657 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of evidence-based guideline for osteoporosis prevention
Number of subjects: 100
Study 22214657 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guideline provided)
Number of subjects: 100
Study 19935406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid at doses of 15, 30, and 50 mg/kg per day
Number of subjects: 18
Study 19935406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 18
Study 17931082 — intervention group
Group type: EXPERIMENTAL
Intervention: Alikal Dolor (effervescent powder containing paracetamol 500 mg/sodium bicarbonate 2318 mg)
Number of subjects: 18
Study 17931082 — intervention group
Group type: COMPARATOR
Intervention: Parageniol (paracetamol 500 mg coated tablets)
Number of subjects: 18
Study 15848672 — intervention group
Group type: COMPARATOR
Intervention: Prograf twice a day (days 14 and 42)
Number of subjects: 70
Study 15848672 — intervention group
Group type: EXPERIMENTAL
Intervention: MR tacrolimus once daily (days 28 and 56)
Number of subjects: 70
Study 15848672 — intervention group
Group type: COMPARATOR
Intervention: Prograf twice a day (day 14)
Number of subjects: 70
Study 15848672 — intervention group
Group type: EXPERIMENTAL
Intervention: MR tacrolimus once daily (day 28)
Number of subjects: 70
Study 15848672 — intervention group
Group type: COMPARATOR
Intervention: Prograf twice a day (day 42)
Number of subjects: 70
Study 15848672 — intervention group
Group type: EXPERIMENTAL
Intervention: MR tacrolimus once daily (day 56)
Number of subjects: 70
Study 15848672 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 70
Study 11973248 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment for up to 6 weeks
Number of subjects: 11
Study 11973248 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment for 4 or more weeks
Number of subjects: 11
Study 8201751 — intervention group
Group type: EXPERIMENTAL
Intervention: pH sensor feeding tube
Number of subjects: 39
Study 8201751 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding tube
Number of subjects: 39
Study 3297575 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group
Number of subjects: 345
Study 3297575 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 345
Study 30717690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ferric Carboxymaltose (FCM)
Number of subjects: 100
Study 30717690 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Iron sucrose complex (ISC)
Number of subjects: 100
Study 28527704 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547659 7.5 mg
Number of subjects: 357
Study 28527704 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547659 22.5 mg
Number of subjects: 357
Study 28527704 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547659 75 mg
Number of subjects: 357
Study 28527704 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547659 225 mg
Number of subjects: 357
Study 28527704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 25746580 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐adrenergic agonist (midodrine) plus an anticholinergic (solifenacin)
Number of subjects: 78
Study 25746580 — intervention group
Group type: COMPARATOR
Intervention: α‐adrenergic agonist only
Number of subjects: 78
Study 22931254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 1983
Study 22931254 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracolumbar X-ray
Number of subjects: 1983
Study 22931254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA) and Thoracolumbar X-ray
Number of subjects: 1983
Study 20950801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic position changes during colonoscope withdrawal
Number of subjects: 130
Study 19463883 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 12
Study 19463883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16974184 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) 10-20 mg/d
Number of subjects: 346
Study 16974184 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine (QUE) 300-700 mg/d
Number of subjects: 346
Study 15223883 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week strength and flexibility program
Number of subjects: 31
Study 15223883 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 11279409 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump treatment on the beating heart
Number of subjects: 200
Study 11279409 — intervention group
Group type: COMPARATOR
Intervention: On-pump treatment with conventional cardiopulmonary bypass
Number of subjects: 200
Study 9253309 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole by a titration regimen (Group A, n = 30)
Number of subjects: 60
Study 9253309 — intervention group
Group type: COMPARATOR
Intervention: Higher doses of carbimazole plus T4 (Group B, n = 30)
Number of subjects: 60
Study 9253309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study 8463869 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide-free diet with 20 g of unabsorbed sugar lactulose
Number of subjects: 12
Study 8463869 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide-free diet with 20 g of fermentable fiber, guar
Number of subjects: 12
Study 8463869 — intervention group
Group type: COMPARATOR
Intervention: Polysaccharide-free diet alone
Number of subjects: 12
Study 2834257 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg every 6 h s.c.)
Number of subjects: 12
Study 2834257 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg every 6 h s.c.)
Number of subjects: 12
Study 2834257 — intervention group
Group type: COMPARATOR
Intervention: Control (saline 1 ml every 6 h s.c.)
Number of subjects: 12
Study 30461007 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-h mortality risk score based on age, sex, haemoglobin level, serum creatinine level, systolic BP, aortic neck length and angle, and acute myocardial ischaemia.
Number of subjects: 536
Study 30461007 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-h mortality risk score
Number of subjects: 536
Study 28158200 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tool (Intervention condition, IC)
Number of subjects: 408
Study 28158200 — intervention group
Group type: COMPARATOR
Intervention: Active control tool (CC)
Number of subjects: 408
Study 28158200 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tool (IC)
Number of subjects: 408
Study 25171663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose triamcinolone hexacetonide (20 mg)
Number of subjects: 60
Study 25171663 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose triamcinolone hexacetonide (40 mg)
Number of subjects: 60
Study 23279923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanca perfume use
Number of subjects: 0
Study 21191857 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 19644905 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic care (NC)
Number of subjects: 85
Study 19644905 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical exercises (PE)
Number of subjects: 85
Study 17654051 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich food (PRF)
Number of subjects: 21
Study 17654051 — intervention group
Group type: COMPARATOR
Intervention: Polyphenol-free food (PFF)
Number of subjects: 21
Study 15089941 — intervention group
Group type: EXPERIMENTAL
Intervention: Protect Liner F
Number of subjects: 52
Study 15089941 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-Dent Desensitizer
Number of subjects: 52
Study 15089941 — intervention group
Group type: COMPARATOR
Intervention: Fluoline varnish
Number of subjects: 52
Study 15089941 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond
Number of subjects: 52
Study 15089941 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 52
Study 11318462 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine, prednisolone and complex B vitamins (Group A)
Number of subjects: 72
Study 11318462 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (Group B)
Number of subjects: 72
Study 11318462 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone and complex B vitamins (Group C)
Number of subjects: 72
Study 9035015 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg bid (E200)
Number of subjects: 426
Study 9035015 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg bid (E300)
Number of subjects: 426
Study 9035015 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg qd (P20)
Number of subjects: 426
Study 7706507 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% CO2 + 35% O2
Number of subjects: 20
Study 7706507 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 20
Study 3667002 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive medical and surgical management
Number of subjects: 1
Study 29566739 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in mental health components of Primary Care 101 (PC101) and clinical communications skills training, supplemented with a clinic-based behavioural health counsellor providing manualised depression counselling (eight sessions, individual or group) and adherence counselling sessions (one session, individual).
Number of subjects: 2000
Study 29566739 — intervention group
Group type: COMPARATOR
Intervention: Control group implementing the South African Department of Health's Integrated Clinical Services Management model, including training in PC101 covering communicable diseases, NCDs, women's health, and mental disorders.
Number of subjects: 2000
Study 26511262 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting wire pathologic duct marking
Number of subjects: 69
Study 26511262 — intervention group
Group type: COMPARATOR
Intervention: Methylene blue pathologic duct marking
Number of subjects: 69
Study 26386790 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban
Number of subjects: 21105
Study 26386790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose edoxaban
Number of subjects: 21105
Study 26386790 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 26386790 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs (meta-analysis of 4 warfarin-controlled phase 3 AF trials)
Number of subjects: 21105
Study 24416747 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid foam 15%
Number of subjects: 0
Study 24416747 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 21534652 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based therapy (TAO)
Number of subjects: 205
Study 21534652 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help (SAO)
Number of subjects: 205
Study 18240190 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderately severe to severe symptoms of depression
Number of subjects: 200
Study 18240190 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients rated by physicians as having worse ACR functional status
Number of subjects: 200